Skip to main content

Table 2 Factors associated with low BMD and fracture at univariate analysis

From: Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients

 

BMD < −1SD

Fracture

 

OR [95% CI]

P

OR [95% CI]

P

Menopause

5.29 [1.83; 15.27]

0.002

2.1 [0.68; 6.53]

0.2

Age, years

1.06 [1.03; 1.1]

<0.001

1.09 [1.05; 1.14]

<0.001

Calcium intake <500 mg/d

4.28 [1.89; 9.72]

<0.001

2.2 [0.93; 5.18]

0.072

Stage NHYA 3 or 4

3.34 [1.3; 8.54]

0.012

3.18 [1.23; 8.2]

0.017

Disease duration

1.05 [1; 1.1]

0.047

1 [0.95; 1.06]

0.9

Cumulative CS dose

1.15 [0.98; 1.36]

0.088

1.2 [0.99; 1.44]

0.059

Current CS treatment

1.68 [0.83; 3.4]

0.15

2.63 [1.08; 6.37]

0.033

Vitamin D supplements

3.82 [1.66; 8.8]

0.002

2.07 [0.87; 4.95]

0.1

BP treatment

3.03 [1.44; 6.36]

0.003

1.83 [0.8; 4.15]

0.15

ESR >10 mm/h

2.49 [1.1; 5.62]

0.028

1.38 [0.55; 3.46

0.5

Lymphocytes >1,000/mm3

0.45 [0.21; 0.94]

0.033

1.19 [0.5; 2.85]

0.7

Creatinine clearance, ml/mn

0.99 [0.98; 1]

0.034

0.97 [0.95; 0.99]

<0.001

25(OH)D serum level

    

25(OH)D ≤10 ng/ml

1

-

1

-

10 < 25(OH)D <20 ng/ml

0.48 [0.21; 1.09]

0.079

1.24 [0.45; 8.23]

0.67

25(OH)D >20 ng/ml

2.00 [0.8; 4.97]

0.13

2.94 [1.05; 8.23]

0.04

Serum PTH level, pmol/l

    

Fracture/low BMD

4.39 [1.86; 10.37]

<0.001

4.39 [1.86; 10.37]

<0.001

  1. BMD, bone mineral density; BP, bisphosphonates; CS, Corticosteroids; ESR, erythrocyte sedimentation rate; PTH, parathyroid hormone; NYHA, New York Heart Association.